Osiris Therapeutics (OTCMKTS: OSIR) and Anavex Life Sciences Corp. (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Earnings and Valuation

This table compares Osiris Therapeutics and Anavex Life Sciences Corp.’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $59.87 million 3.36 -$1.78 million N/A N/A
Anavex Life Sciences Corp. N/A N/A -$14.73 million ($0.39) -10.18

Osiris Therapeutics has higher revenue and earnings than Anavex Life Sciences Corp..

Insider and Institutional Ownership

0.3% of Osiris Therapeutics shares are held by institutional investors. Comparatively, 24.4% of Anavex Life Sciences Corp. shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by insiders. Comparatively, 11.6% of Anavex Life Sciences Corp. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Osiris Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp. has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Osiris Therapeutics and Anavex Life Sciences Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics N/A N/A N/A
Anavex Life Sciences Corp. N/A -95.68% -84.88%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Osiris Therapeutics and Anavex Life Sciences Corp., as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Anavex Life Sciences Corp. 0 0 2 0 3.00

Anavex Life Sciences Corp. has a consensus price target of $15.00, suggesting a potential upside of 277.83%. Given Anavex Life Sciences Corp.’s higher possible upside, analysts plainly believe Anavex Life Sciences Corp. is more favorable than Osiris Therapeutics.

Summary

Osiris Therapeutics beats Anavex Life Sciences Corp. on 5 of the 9 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for Osiris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.